Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

RNAZ

TransCode Therapeutics (RNAZ)

TransCode Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RNAZ
DateTimeSourceHeadlineSymbolCompany
03/13/20257:47AMPR Newswire (US)TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical TrialNASDAQ:RNAZTransCode Therapeutics Inc
02/25/20254:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
02/25/20254:15PMPR Newswire (US)TransCode Therapeutics, Inc. Announces Results of Special MeetingNASDAQ:RNAZTransCode Therapeutics Inc
02/06/20258:00AMPR Newswire (US)TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical TrialNASDAQ:RNAZTransCode Therapeutics Inc
02/04/20254:21PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
02/04/20254:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
02/04/20254:15PMPR Newswire (US)TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special MeetingNASDAQ:RNAZTransCode Therapeutics Inc
01/14/20258:00AMPR Newswire (US)TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical TrialNASDAQ:RNAZTransCode Therapeutics Inc
01/07/20258:00AMPR Newswire (US)Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsNASDAQ:RNAZTransCode Therapeutics Inc
12/30/20245:08PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
12/20/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
12/19/20244:48PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
12/18/20248:00AMPR Newswire (US)TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical TrialNASDAQ:RNAZTransCode Therapeutics Inc
12/18/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RNAZTransCode Therapeutics Inc
12/12/20244:15PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RNAZTransCode Therapeutics Inc
12/06/20245:05PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:RNAZTransCode Therapeutics Inc
12/02/20244:27PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
11/29/20244:25PMGlobeNewswire Inc.TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock SplitNASDAQ:RNAZTransCode Therapeutics Inc
11/29/20244:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
11/27/20247:00AMGlobeNewswire Inc.TransCode Therapeutics, Inc. Announces $8 Million Private PlacementNASDAQ:RNAZTransCode Therapeutics Inc
11/25/20247:54AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
11/25/20247:00AMGlobeNewswire Inc.TransCode Therapeutics Announces 1-for-33 Reverse Stock SplitNASDAQ:RNAZTransCode Therapeutics Inc
11/13/20244:34PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
11/12/20247:00AMGlobeNewswire Inc.TransCode Therapeutics Open Letter to ShareholdersNASDAQ:RNAZTransCode Therapeutics Inc
11/06/20244:05PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
11/06/20244:01PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
11/06/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
11/05/20247:00AMGlobeNewswire Inc.TransCode Therapeutics Announces Nasdaq Extension to Regain ComplianceNASDAQ:RNAZTransCode Therapeutics Inc
10/28/20244:02PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
10/23/20247:00AMGlobeNewswire Inc.TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety DataNASDAQ:RNAZTransCode Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RNAZ